Intralesional rituximab in the treatment of indolent primary cutaneous B-cell lymphomas: an epidemiological observational multicentre study. The Spanish Working Group on Cutaneous Lymphoma

Summary Background Intravenous rituximab is a safe and effective option for the treatment of systemic non‐Hodgkin B‐cell lymphoma. The effectiveness of intralesional rituximab (ILR) in primary cutaneous B‐cell lymphomas (PCBL) has been described in a small number of patients. Objectives To evaluat...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of dermatology (1951) 2012-07, Vol.167 (1), p.174-179
Hauptverfasser:	Peñate, Y., Hernández-Machín, B., Pérez-Méndez, L.I., Santiago, F., Rosales, B., Servitje, O., Estrach, T., Fernández-Guarino, M., Calzado, L., Acebo, E., Gallardo, F., Salar, A., Izu, R., Ortiz-Romero, P.L., Pujol, R.M., Fernández-de-Misa, R.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antibodies, Monoclonal, Murine-Derived - administration & dosage Antineoplastic Agents - administration & dosage Biological and medical sciences Dermatology Disease-Free Survival Epidemiology Female General aspects Hematologic and hematopoietic diseases Humans Injections, Intralesional Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Lymphoma, B-Cell - drug therapy Male Medical sciences Middle Aged Public health. Hygiene Public health. Hygiene-occupational medicine Rituximab Skin Neoplasms - drug therapy Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!